Liquidia (LQDA) Stock Price, News & Analysis

Company Overview

Liquidia Technologies, Inc. is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH). LIQ861 aims to offer a more convenient and potentially more consistent dosing approach compared with current liquid-based nebulized therapies. Besides PAH, Liquidia is exploring additional indications and dosage forms to expand the use of its PRINT platform, including collaborations focused on vaccine adjuvants and other respiratory applications.

Liquidia Technologies was founded to translate advanced particle-engineering science into therapeutic benefit and has assembled a team with experience in respiratory drug development, regulatory affairs and clinical operations. The company conducts clinical research primarily in the United States, and it plans to pursue regulatory filings in major markets following the completion of pivotal studies. Under the leadership of President and CEO Chris Critelli, Liquidia continues to advance its pipeline toward potential commercialization.

Key Stats

• Today's Range: $59.95 to $61.83
• 50-Day Range: $35.03 to $61.77
• 52-Week Range: $11.85 to $62.17
• Volume: 673,754 shs
• Average Volume: 1.70 million shs
• Market Capitalization: $5.44 billion
• P/E Ratio: 436.78
• Dividend Yield: N/A
• Price Target: $49.33
• Consensus Rating: Moderate Buy

Liquidia Stock Analysis - MarketRank™

Liquidia scored higher than 67% of companies evaluated by MarketBeat, and ranked 329th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Liquidia has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 3 strong buy ratings, 7 buy ratings, no hold ratings, and 2 sell ratings.

Downside Risk

Liquidia has a consensus price target of $49.33, representing about 19.1% downside from its current price of $61.02.

Amount of Analyst Coverage

Liquidia has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 61.95%

Earnings Growth

Earnings for Liquidia are expected to grow by 61.95% in the coming year, from $2.97 to $4.81 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Liquidia is 435.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Liquidia is 435.87, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.88.

Price to Book Value per Share Ratio

Liquidia has a P/B Ratio of 50.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.04% of the float of Liquidia has been sold short.

Short Interest Ratio / Days to Cover

Liquidia has a short interest ratio ("days to cover") of 9.79.

Change versus previous month

Short interest in Liquidia has recently decreased by 12.86%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Liquidia does not currently pay a dividend.

Dividend Growth

Liquidia does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.67

News Sentiment

Liquidia has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 15 news articles for Liquidia this week, compared to 7 articles on an average week.

Search Interest

Only 4 people have searched for LQDA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

5 people have added Liquidia to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Liquidia insiders have sold 14,419.31% more of their company's stock than they have bought. Specifically, they have bought $317,894.00 in company stock and sold $46,156,003.00 in company stock.

Percentage Held by Insiders

25.60% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

64.54% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 5/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:LQDA
• CIK: 1819576
• Web: www.liquidia.com
• Phone: (919) 328-4400
• Fax: N/A
• Employees: 50
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Liquidia: $49.33
• High Price Target: $70.00
• Low Price Target: $19.00
• Potential Upside/Downside: -19.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.14
• Trailing P/E Ratio: 436.78
• Forward P/E Ratio: 20.60
• P/E Growth: N/A
• Net Income: -$68.92 million
• Net Margins: 7.74%
• Pretax Margin: 9.10%
• Return on Equity: 46.82%
• Return on Assets: 7.06%

Debt

• Debt-to-Equity Ratio: 1.18
• Current Ratio: 2.22
• Quick Ratio: 2.03

Sales & Book Value

• Annual Sales: $158.32 million
• Price / Sales: 34.37
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.22 per share
• Price / Book: 50.15

Miscellaneous

• Outstanding Shares: 88,930,000
• Free Float: 66,162,000
• Market Cap: $5.44 billion
• Optionable: Optionable
• Beta: 0.41